193 related articles for article (PubMed ID: 22908929)
1. Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo.
Shi Q; Kuether EL; Schroeder JA; Perry CL; Fahs SA; Cox Gill J; Montgomery RR
J Thromb Haemost; 2012 Nov; 10(11):2328-37. PubMed ID: 22908929
[TBL] [Abstract][Full Text] [Related]
2. The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies.
Shi Q; Schroeder JA; Kuether EL; Montgomery RR
J Thromb Haemost; 2015 Jul; 13(7):1301-9. PubMed ID: 25955153
[TBL] [Abstract][Full Text] [Related]
3. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the von Willebrand factor/factor VIII complex produced by a novel purification process.
Ahn JW; Chang ES; Jung YJ; Kim SR; Seong BL; Ha SH
Arch Pharm Res; 2020 Jul; 43(7):714-723. PubMed ID: 32666302
[TBL] [Abstract][Full Text] [Related]
5. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
6. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
7. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
[TBL] [Abstract][Full Text] [Related]
8. Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development.
Mannucci PM; Shi Q; Bonanad S; Klamroth R
Haemophilia; 2014 Sep; 20 Suppl 6():2-16. PubMed ID: 24975700
[TBL] [Abstract][Full Text] [Related]
9. Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice.
Vollack-Hesse N; Oleshko O; Werwitzke S; Solecka-Witulska B; Kannicht C; Tiede A
Blood; 2021 Feb; 137(8):1072-1081. PubMed ID: 32877516
[TBL] [Abstract][Full Text] [Related]
10. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
12. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors.
Bravo MI; Da Rocha-Souto B; Grancha S; Jorquera JI
Haemophilia; 2014 Nov; 20(6):905-11. PubMed ID: 25156825
[TBL] [Abstract][Full Text] [Related]
13. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
14. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
Yee A; Gildersleeve RD; Gu S; Kretz CA; McGee BM; Carr KM; Pipe SW; Ginsburg D
Blood; 2014 Jul; 124(3):445-52. PubMed ID: 24850761
[TBL] [Abstract][Full Text] [Related]
15. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
16. Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interaction.
Batlle J; Lourés E; Vila P; Hernández MC; Méndez JA; Torea J; Rendal E; Couselo MJ; Filgueira A; López Fernández MF
Ann Hematol; 1997 Sep; 75(3):111-5. PubMed ID: 9368480
[TBL] [Abstract][Full Text] [Related]
17. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
18. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
[TBL] [Abstract][Full Text] [Related]
19. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo.
van Schooten CJ; Shahbazi S; Groot E; Oortwijn BD; van den Berg HM; Denis CV; Lenting PJ
Blood; 2008 Sep; 112(5):1704-12. PubMed ID: 18559674
[TBL] [Abstract][Full Text] [Related]
20. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
Bravo MI; Pérez A; Raventós A; Grancha S; Jorquera JI; Butta NV; Álvarez-Román MT; Costa M; Willis T; Jiménez-Yuste V
Haemophilia; 2022 Sep; 28(5):737-744. PubMed ID: 35654086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
